Fresenius Medical Care AG & Co. (FMS)
(Delayed Data from NYSE)
$21.30 USD
+0.04 (0.19%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $21.28 -0.02 (-0.09%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Brokerage Reports
0 items in cart
Fresenius Medical Care AG & Co. KGaA [FMS]
Reports for Purchase
Showing records 101 - 120 ( 142 total )
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Discontinuation of Research Coverage
Provider: FELTL & COMPANY
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Inline 4Q13 results; 2014 guidance fails to impress as margin pressure increases
Provider: FELTL & COMPANY
Analyst: WEIGHT M
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
CMS finalized dialysis rebasing with a four year phase-in period
Provider: FELTL & COMPANY
Analyst: WEIGHT M
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
3Q13 largely inline with expectations; rebasing overhang continues
Provider: FELTL & COMPANY
Analyst: WEIGHT M
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Company: Fresenius Medical Care AG & Co. KGaA
Industry: Medical - Instruments
Fireworks start early as CMS proposed ESRD rule worse than expected
Provider: FELTL & COMPANY
Analyst: WEIGHT M